MedTrace Logo

Dornase Alfa Administered to Patients With COVID-19 (DACOVID)

NCT04387786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-11-13

No results posted yet for this study

Summary

Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19-acting as a mucolytic and targeting NETs.

Conditions

Interventions

DRUG

Dornase Alfa

nebulized in-line endotracheal dornase alfa co-administered with albuterol

Sponsors & Collaborators

Principal Investigators

  • Betsy J Barnes · Feinstein Institute for Medical Research

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-04-24
Completion
2020-09-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387786 on ClinicalTrials.gov